Table 1.
Association of Higher HLA Class-I APM Component Expression Level in Cancer Cells with Better Survival Outcomes.
| Cancer Type | Component | Survival Outcome | Reference1 |
|---|---|---|---|
|
| |||
| Bladder | Calreticulin | OS | Cathro et al. (2010) |
| Breast | HLA class-I | DSS | Sik Park et al. (2019) |
| Cervical | HLA-A, HLA class-I, LMP7, TAP1, ERAP1 | OS | Mehta et al. (2008) |
| Cervical | HLA-A, TAP1, ERAP1 | DFS | Mehta et al. (2008) |
| Clear Cell RCC | HLA class-I | OS, RFS | Sekar et al. (2016) |
| Colon | HLA-A, HLA-C | DFS | Benevolo et al. (2007) |
| Colon | HLA-C | OS | Benevolo et al. (2007) |
| Colon | Calreticulin | OS | Peng et al. (2010) |
| Colorectal | HLA class-I | DFS | Iwayama et al. (2015) |
| Colorectal | HLA-A | DFS | Sandel et al. (2005) |
| Colorectal | HLA class-I | DSS | Simpson et al. (2010) |
| Colorectal | Tapasin | OS | Sokol et al. (2015) |
| Colorectal | HLA-B/C+B2M co-expression | DSS | Watson et al. (2006) |
| Endometrial | HLA-B/C | PFS, OS | Yakabe et al. (2015) |
| ESFT | HLA class-I | OS | Yabe et al. (2011) |
| Esophageal | HLA class-I | RFS | Hosch et al. (1997) |
| Esophageal | HLA class-I, B2M, TAP1 | OS | Tanaka et al. (2012) |
| Esophageal SCC | HLA class-I | OS | Mizukami et al. (2008) |
| Esophageal SCC | HLA class-I | OS | Zhang et al. (2013) |
| Gastric | HLA class-I | OS | Ishigami et al. (2008) |
| Gastric | ERp57 | OS | Leys et al. (2007) |
| HCC | HLA-C | OS | Wang et al. (2019) |
| HNSCC | HLA-B/C | DFS | Bandoh et al. (2010) |
| HR-proficient ovarian | HLA class-I | PFS | Matsushita et al. (2020) |
| Laryngeal SCC | HLA-B/C, B2M, LMP2 | DFS, CSS | Ogino et al. (2006) |
| Maxillary Sinus SCC | Tapasin, HLA-B/C | OS | Ogino et al. (2003) |
| Melanoma | TAP1, TAP2, HLA-B/C | PFS, OS | Kageshita et al. (1999) |
| NSCLC | HLA class-I | OS | Ichinokawa et al. (2019) |
| NSCLC | HLA class-I | OS | Kikuchi et al. (2007) |
| Osteosarcoma | HLA class-I | OS, EFS | Tsukahara et al. (2006) |
| PDAC | HLA-B/C | OS | Michelakos et al. (2021) |
| Penile | HLA-A | OS | Djajadiningrat et al. (2015) |
| Prostate | HLA class-I | OS | Levin et al. (1994) |
| Rectal | HLA class-I | DFS | Reimers et al. (2014) |
| Rectal | HLA class-I | OS, DFS | Speetjens et al. (2008) |
Citations provided in Supplementary Information.
Abbreviations: B2M, beta 2-microglobulin; CSS, cause-specific survival; DFS, disease-free survival; DSS, disease-specific survival; EFS, event-free survival; ERAP, endoplasmic reticulum aminopeptidase; ERp57, endoplasmic reticulum resident protein 57; ESFT, Ewing sarcoma family of tumors; HCC, hepatocellular carcinoma; HLA, human leukocyte antigen; HNSCC, head and neck squamous cell carcinoma; HR, homologous recombination; NSCLC, non-small-cell lung cancer; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival; RCC, renal cell carcinoma; RFS, relapse-free survival; SCC, squamous cell carcinoma; TAP, transporter associated with antigen processing.